ArticleFrontiers in medicine2026
Effectiveness of 0.05% cyclosporine A eye drops for dry eye disease in patients with thyroid-associated ophthalmopathy: a prospective, parallel-group cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid-associated ophthalmopathy (TAO) is frequently accompanied by dry eye disease (DED), which can lead to ocular surface damage and decreased visual quality. This study aimed to evaluate the effectiveness of 0.05% cyclosporine A (CsA) eye drops in the treatment of TAO-related DED. Methods: This prospective, parallel-group cohort study included 86 participants diagnosed with TAO-related DED. Participants were divided into either the CsA group ( Results: After 3 months of treatment, the CsA group demonstrated significantly better outcomes than the control group in ocular surface disease index (OSDI) scores, fluorescein tear breakup time (FBUT), and Schirmer I test (SIT) values (all Conclusion: 0.05% CsA eye drops were associated with improvement in tear film stability, tear secretion, and corneal epithelial integrity in participants with TAO-related DED, and were well tolerated over the 3-month follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.